DaVita (NYSE:DVA) Updates FY24 Earnings Guidance

DaVita (NYSE:DVA) issued an update on its FY24 earnings guidance on Thursday morning. The company provided earnings per share guidance of $9.00-$9.80 for the period, compared to the consensus earnings per share estimate of $9.30.

DaVita Trading Down 5.5 %

DVA stock traded down $7.79 during trading on Friday, hitting $134.45. The company had a trading volume of 2,541,405 shares, compared to its average volume of 628,593. The firm has a market capitalization of $11.79 billion, a P/E ratio of 15.28, a PEG ratio of 1.20 and a beta of 1.04. DaVita has a 52-week low of $71.51 and a 52-week high of $145.04. The company has a 50 day simple moving average of $133.71 and a 200-day simple moving average of $112.84. The company has a quick ratio of 1.13, a current ratio of 1.19 and a debt-to-equity ratio of 6.65.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $2.38 EPS for the quarter, topping the consensus estimate of $1.95 by $0.43. The company had revenue of $3.07 billion for the quarter, compared to the consensus estimate of $3.03 billion. DaVita had a net margin of 6.61% and a return on equity of 66.59%. The firm’s revenue was up 6.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.58 EPS. As a group, research analysts forecast that DaVita will post 9.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

DVA has been the topic of a number of recent analyst reports. TheStreet upgraded shares of DaVita from a c+ rating to a b- rating in a report on Wednesday, February 7th. Barclays initiated coverage on shares of DaVita in a report on Wednesday, March 6th. They issued an equal weight rating and a $133.00 price target on the stock. UBS Group raised their price target on shares of DaVita from $113.00 to $134.00 and gave the company a buy rating in a report on Wednesday, February 14th. Truist Financial lifted their target price on shares of DaVita from $130.00 to $135.00 and gave the stock a hold rating in a research note on Tuesday, February 20th. Finally, StockNews.com upgraded shares of DaVita from a buy rating to a strong-buy rating in a research note on Thursday, April 25th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of Moderate Buy and an average target price of $118.50.

Insider Buying and Selling

In other news, CEO Javier Rodriguez sold 67,603 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the transaction, the chief executive officer now directly owns 488,697 shares in the company, valued at $61,629,578.67. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, COO Michael David Staffieri sold 29,488 shares of DaVita stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $119.81, for a total value of $3,532,957.28. Following the sale, the chief operating officer now owns 37,687 shares of the company’s stock, valued at $4,515,279.47. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Javier Rodriguez sold 67,603 shares of DaVita stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the completion of the sale, the chief executive officer now directly owns 488,697 shares in the company, valued at approximately $61,629,578.67. The disclosure for this sale can be found here. Insiders sold a total of 134,540 shares of company stock worth $16,551,071 over the last 90 days. 1.40% of the stock is owned by insiders.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.